These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 10052471)

  • 1. Mycophenolate-update after it has come of age.
    Grinyó JM
    Nephrol Dial Transplant; 1999 Jan; 14(1):31-4. PubMed ID: 10052471
    [No Abstract]   [Full Text] [Related]  

  • 2. Mycophenolate mofetil for prevention of acute rejection.
    Winearls CG
    Lancet; 1995 Jul; 346(8969):253-4. PubMed ID: 7616828
    [No Abstract]   [Full Text] [Related]  

  • 3. Meta-analysis of FK 506 and mycophenolate mofetil refractory rejection trials in renal transplantation. Refractory Rejection Meta-Analysis Study Group.
    Woodle ES; Jordan ML; Facklam D; Shapiro R; Danovitch GM
    Transplant Proc; 1998 Jun; 30(4):1297-8. PubMed ID: 9636526
    [No Abstract]   [Full Text] [Related]  

  • 4. Mycophenolate mofetil reduces graft loss due to chronic allograft nephropaty.
    Falkiewicz K; Kuriata M; Boratyńska M; Klinger M; Szepietowski T; Patrzałek D; Szyber P
    Transplant Proc; 2002 Mar; 34(2):567-8. PubMed ID: 12009626
    [No Abstract]   [Full Text] [Related]  

  • 5. The incidence of subsequent acute rejection following the treatment of refractory renal allograft rejection with mycophenolate mofetil (RS61443).
    Laskow DA; Deierhoi MH; Hudson SL; Orr CL; Curtis JJ; Diethelm AG
    Transplantation; 1994 Feb; 57(4):640-3. PubMed ID: 8116055
    [No Abstract]   [Full Text] [Related]  

  • 6. Cytokine analysis before and after mycophenolate mofetil treatment in renal transplantation.
    Oliveira JG; Sampaio S; Xavier P; Aragão P; Mendes A; Guerra L
    Transplant Proc; 2000 Dec; 32(8):2631-2. PubMed ID: 11134732
    [No Abstract]   [Full Text] [Related]  

  • 7. Humoral immune response after kidney transplantation is enhanced by acute rejection and urological obstruction and is down-regulated by mycophenolate mofetil treatment.
    Oliveira JG; Monteiro MS; Teixeira JF; Osório E; Norton SM; Alves H; Pestana M
    Transpl Int; 2005 Nov; 18(11):1286-91. PubMed ID: 16221160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reversal of acute allograft rejection using immunotoxin.
    Knechtle SJ; Fechner JH; Stavrou S; Neville DM; Dong Y; Hong X; Tsuchida M; Hamawy MM
    Transplant Proc; 1998 Aug; 30(5):2150-1. PubMed ID: 9723422
    [No Abstract]   [Full Text] [Related]  

  • 9. Mycophenolate mofetil. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in renal transplantation.
    Fulton B; Markham A
    Drugs; 1996 Feb; 51(2):278-98. PubMed ID: 8808168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Questionable long-term benefit of mycophenolate.
    Steiner RW
    Transplantation; 2000 Jul; 70(2):401. PubMed ID: 10933174
    [No Abstract]   [Full Text] [Related]  

  • 11. Mycophenolate mofetil for prevention of acute rejection.
    Moore R; Griffin P; Darby C; Jurewicz A; Lord R
    Lancet; 1995 Jul; 346(8969):253. PubMed ID: 7616827
    [No Abstract]   [Full Text] [Related]  

  • 12. The case of azathioprine versus mycophenolate. Do different drugs really cause different transplant outcomes?
    Craig JC; Webster AC; McDonald SP
    Transplantation; 2009 Mar; 87(6):803-4. PubMed ID: 19300180
    [No Abstract]   [Full Text] [Related]  

  • 13. Mycophenolate mofetil in pediatric renal transplantation.
    Otukesh H; Sharifian M; Basiri A; Simfroosh N; Hoseini R; Sedigh N; Golnari P; Rezai M; Fereshtenejad M
    Transplant Proc; 2005 Sep; 37(7):3012-5. PubMed ID: 16213289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of severe acute vascular rejection in a renal allograft with mycophenolate mofetil and high dose steroids.
    Lafferty ME; Lang S; McGregor E; Henderson IS; Jones MC
    Scott Med J; 1997 Jun; 42(3):79-80. PubMed ID: 9351121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Steroid sparing strategies in renal transplantation.
    Grinyó JM
    Nephrol Dial Transplant; 2005 Oct; 20(10):2028-31. PubMed ID: 16105871
    [No Abstract]   [Full Text] [Related]  

  • 16. Effects of mycophenolate mofetil on hematocrit after renal transplantation.
    Chenhsu RY; Wu YM; Min DI; Zimmerman MB
    Ann Pharmacother; 2002 Sep; 36(9):1479-80. PubMed ID: 12196073
    [No Abstract]   [Full Text] [Related]  

  • 17. Primary tuberculosis 1 year after conversion from azathioprine to mycophenolate in recipient kidney transplantation: a case report.
    Skhiri H; Guedri Y; Souani Y; Achour A; Bouraoui S; Frih A; Dhia BN; Elmay M
    Transplant Proc; 2003 Nov; 35(7):2678-9. PubMed ID: 14612069
    [No Abstract]   [Full Text] [Related]  

  • 18. MYSS: should we alter clinical practice?
    Maes B; Vanrenterghem Y
    Lancet; 2004 Dec 4-10; 364(9450):2016-7; author reply 2017-8. PubMed ID: 15582052
    [No Abstract]   [Full Text] [Related]  

  • 19. One-year follow-up results of a phase I trial of mycophenolate mofetil (RS61443) in cadaveric renal transplantation.
    Deierhoi MH; Sollinger HW; Diethelm AG; Belzer FO; Kauffman RS
    Transplant Proc; 1993 Feb; 25(1 Pt 1):693-4. PubMed ID: 8438440
    [No Abstract]   [Full Text] [Related]  

  • 20. The role of mycophenolate mofetil in kidney transplantation revisited.
    Maripuri S; Kasiske BL
    Transplant Rev (Orlando); 2014 Jan; 28(1):26-31. PubMed ID: 24321304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.